Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Larotrectinib

11b8fa69-6ec8-5173-86ec-5e7747041ef6 · FDA Approved · targets TRKA, TRKB, TRKC

Larotrectinib

MeasuredReference

Larotrectinib targets NTRK1, NTRK3, NTRK2. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

NTRK1NTRK3NTRK2ROS_ROS1

Top hallmarks

  • tumor promoting inflammation739
  • proliferation665
  • evading apoptosis649

Top pathways disrupted

  • pi3k akt mtor signaling1.4k
  • apoptosis1.2k
  • apical junction1.2k

Resistance landscape — Larotrectinib

MeasuredReference

10 known oncogenic variants exist on Larotrectinib's top targets — see detail for inhibition impact.

Open in new tab